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Psoriasis is an inflammatory skin disease driven by
aberrant interactions between the epithelium and the
immune system. Anti-psoriatic drugs can therefore
target either the keratinocytes or the immunocytes.
Here we sought to develop an in vitro reconstructed
skin model that would display the molecular charac-
teristics of psoriatic epidermis in a controlled man-
ner, allowing the screening of anti-psoriatic drugs
and providing a model in which to study the biology
of this disease. Human skin equivalents generated
from normal human adult keratinocytes after air ex-
posure and stimulation by keratinocyte growth factor
and epidermal growth factor displayed the correct
morphological and molecular characteristics of nor-
mal human epidermis whereas the psoriasis-associ-
ated proteins, hBD-2, SKALP/elafin, and CK16, were
absent. Skin equivalents generated from foreskin ker-
atinocytes were clearly abnormal both morphologi-
cally and with respect to gene expression. When nor-
mal skin equivalents derived from adult keratinocytes
were stimulated with psoriasis-associated cytokines
[tumor necrosis factor- , interleukin (IL)-1 , IL-6,
and IL-22] or combinations thereof, strong expres-
sion of hBD-2, SKALP/elafin, CK16, IL-8, and tumor
necrosis factor- was induced as shown by quantita-
tive polymerase chain reaction and immunohisto-
chemistry. Retinoic acid but not cyclosporin A was
found to inhibit cytokine-induced gene expression at
both the mRNA and protein levels. These results illus-
trate the potential of this disease model to study the
molecular pathology and pharmacological interven-
tion in vitro. (Am J Pathol 2008, 173:815–823; DOI:
10.2353/ajpath.2008.080173)
Psoriasis is a highly prevalent inflammatory skin disease
that has both environmental and genetic components to
its etiology.1 Linkage analysis has been used to identify
multiple loci and alleles that confer risk of the disease,
with the strongest genetic effect found at chromosome
6p21.3, where haplotypes carrying the HLA-Cw6 allele
are associated with an increase in risk.2 Recently we
have found that increased -defensin copy numbers are
associated with psoriasis, suggesting that both the adap-
tive immune system and the epidermal innate immune sys-
tem are causally involved in the disease.3 Psoriasis is char-
acterized by erythro-squamous plaques, and histological
examination of psoriatic lesions shows inflammation, in-
creased proliferation, and disturbed epidermal differentia-
tion.4 At the molecular level, a regenerative epidermal dif-
ferentiation program is induced that includes expression of
psoriasis-associated genes such as cytokeratin 16 (CK16),
SKALP/elafin, psoriasin, and -defensin-2 (hBD-2).5 Fur-
thermore, high levels of proinflammatory cytokines and che-
mokines have been demonstrated, including interferon-,
interleukin (IL)-1, tumor necrosis factor (TNF)-, IL-6, and
IL-22, which are produced by multiple cell types.6–10 A
wide array of mechanistically distinct anti-psoriatic thera-
pies is available, including agents that presumably target
the adaptive immune system (corticosteroids, UVB, PUVA,
calcineurin inhibitors), agents that are thought to be di-
rected to the keratinocyte (retinoids, vitamin D3 derivatives,
dithranol) and agents that possibly target multiple cell types
(methotrexate, anti-TNF).4,11–13 Although the anti-psoriatic
armamentarium has been expanded throughout the last
years there is still room for improvement with regard to
efficacy and side effects. The development of relevant,
high-content in vitromodels would greatly enhance the eval-
uation of novel therapeutic agents.
Submerged keratinocyte culture systems have been
widely used for biological and pharmacological studies and
some of these have been developed for high-throughput
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screening of anti-psoriatic drugs.14–16 Recent studies intro-
duced more advanced systems such as three-dimensional
tissue-engineered human skin equivalents.17 Tissue-engi-
neered skin equivalents were initially developed for treat-
ment of skin defects such as burn wounds and ulcers, but
have also made a great impact on basic and applied re-
search.17 Commercially available skin equivalents, mostly
derived from foreskin keratinocytes, mimic normal skin to a
large extent and are used in a wide range of biological
studies, skin corrosion testing, and irritation studies.18 el-
Ghalbzouri and colleagues19 have described the develop-
ment of skin equivalents using de-epidermized dermis
(DED) and adult keratinocytes. The addition of fibroblasts or
defined growth factors to the equivalents stimulated the
development of a good morphology of the epithelium. How-
ever, in contrast to normal skin, the psoriasis-associated
markers SKALP/elafin and cytokeratin 6 were still present in
this model. More recent studies have introduced skin equiv-
alent models for diseased skin, by using keratinocytes from
psoriasis patients,20 induction of a psoriatic phenotype by
inhibition of transglutaminases,21 or by the addition of lym-
phocytes.22 All these models exhibit features of psoriatic
epidermis and some of them were validated by anti-psori-
atic agents.
Here we aimed to generate a reconstructed skin model
from normal adult human keratinocytes, that would allow
controlled induction of psoriasis-associated features and
gene expression by the addition of relevant pro-inflamma-
tory cytokines. The system should allow quantitative mea-
surement of established psoriasis markers in the epidermal
keratinocytes. Preferably, the starting point should be re-
constructed skin that would mimic normal skin both mor-
phologically and with respect to gene expression, as de-
fined by the expression of establishedmarker genes (CK10,
involucrin, loricrin) and the absence of psoriasis-associated
markers (hBD-2, SKALP/elafin, CK16) and low expression
levels of psoriasis-associated pro-inflammatory cytokines
such as IL-8 and TNF-. Here we describe a model system
that fulfills these criteria and that is potentially useful for
studying biology of the disease and screening of anti-pso-
riatic drugs.
Materials and Methods
Cell Culture
Cells from themouse fibroblast cell line 3T3 were cultured in
Dulbecco’s modified Eagle’s medium (Life Technologies,
Inc., Grand Island, NY) supplemented with penicillin/strep-
tomycin (50 IU/ml; ICN Biomedicals, Zoetermeer, The Neth-
erlands) and 10% calf serum with iron (Hyclone, Logan, UT).
Keratinocytes were obtained from human abdominal skin
derived from donors who underwent surgery for abdominal
wall correction. After isolation by trypsin treatment for 16 to
20 hours at 4°C, keratinocytes were cultured in the pres-
ence of irradiated (3295 cGy for 4.10minutes) cells from the
3T3 cell line. 3T3 cells were seeded at a concentration of
3  104 cells per cm2 in Greens medium, which consisted
of two parts Dulbecco’s modified Eagle’s medium (Life
Technologies, Inc.) and one part of Ham’s F12medium (Life
Technologies, Inc.) supplemented with 10% fetal bovine
serum (Hyclone), L-glutamine (4 mmol/L; Life Technologies,
Inc.), penicillin/streptomycin (50 IU/ml; Life Technologies,
Inc.), adenine (24.3 g/ml; Calbiochem, San Diego, CA),
insulin (5 g/ml; Sigma, St. Louis, MO), hydrocortisone (0.4
g/ml; Merck, Darmstadt, Germany), triiodothyronine (1.36
ng/ml, Sigma) and cholera toxin (1010 mol/L, Sigma). The
next day keratinocytes were added at a concentration of
5  104 cells per cm2. After 3 days, medium was replaced
by Greens medium containing epidermal growth factor
(EGF, 10 ng/ml; Sigma). The cells were then refreshed
every 2 to 3 days, and when wells were almost confluent,
cells were trypsinized and stored in the liquid nitrogen.
De-Epidermized Dermis (DED)
DED was generated using abdominal skin from donors
who underwent surgery for abdominal wall correction.
After incubation of the skin for 5 to 10 minutes in phos-
phate-buffered saline (PBS) at 56°C, the epidermis was
separated from the dermis. The dermis was then incu-
bated for 1 month in PBS containing gentamicin (0.5
mg/ml; Life Technologies, Inc.) and antibiotic/antimycotic
(Life Technologies, Inc.) at 37°C. Punches were prepared
from this DED using an 8-mm biopter. DED still contained
basal membrane, as demonstrated by expression of hep-
arin sulfate and collagen type IV.
Generation of Human Skin Equivalents
A hollow metal ring with a diameter of 1 cm was placed on
the DED, and 2 105 keratinocytes were seeded in the ring
in medium containing 5% serum, consisting of two parts
Dulbecco’s modified Eagle’s medium (Life Technologies,
Inc.) and one part Ham’s F12 medium (Life Technologies,
Inc.) supplemented with 5% calf serum (Hyclone), L-glu-
tamine (4 mmol/L, Life Technologies, Inc.), penicillin/strep-
tomycin (50 IU/ml, Life Technologies, Inc.), adenine (24.3
g/ml, Calbiochem), ascorbic acid (50 g/ml, Sigma), in-
sulin (0.2 mol/L, Sigma), hydrocortisone (1 mol/L,
Merck), triiodothyronine (1.36 ng/ml, Sigma), and cholera
toxin (1010 mol/L, Sigma). After 1 day, the ring was re-
moved, and the construct was cultured submerged for 3
days. Then, the skin equivalents were placed on a grid, and
cultured for 10 days at the air-liquid interface in medium
without serum, consisting of two parts Dulbecco’s modified
Eagle’s medium (Life Technologies, Inc.) and one part
Ham’s F12 medium (Life Technologies, Inc.) supplemented
with L-glutamine (4 mmol/L, Life Technologies, Inc.), peni-
cillin/streptomycin (50 IU/ml, Life Technologies, Inc.), ade-
nine (24.3 g/ml, Calbiochem), L-serine (1 mg/ml, Sigma),
L-carnitine (2g/ml, Sigma), BSA lipid mix (palmitic acid (25
mol/L, Sigma), arachidonic acid (7mol/L, Sigma), linoleic
acid (15 mol/L, Sigma), vitamin E (0.4 g/ml, Sigma),
ascorbic acid (50 g/ml, Sigma), insulin (0.1 mol/L,
Sigma), hydrocortisone (1 mol/L, Merck), triiodothyronine
(1.36 ng/ml, Sigma), cholera toxin (1010 mol/L, Sigma),
keratinocyte growth factor (KGF) (5 ng/ml, Sigma) and epi-
dermal growth factor (2 ng/ml, Sigma). Psoriatic skin equiv-
alents were obtained by incubating normal skin equivalents
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the last 4 days of the air-liquid interface culture with various
combinations of cytokines, including IL-1 (Preprotech,
Rocky Hill, NJ), TNF- (Preprotech), IL-6 (2  108 IU/ml;
Gentaur, Brussels, Belgium), and IL-22 (Preprotech).
Quantitative Real-Time Polymerase Chain
Reaction (PCR)
Epidermis was separated for the skin equivalents by
dispase (Roche Diagnostics, Mannheim, Germany) treat-
ment for 4 hours at 4°C, and total RNA was isolated from
the epidermis using Trizol reagent (Life Technologies,
Gaithersburg, MD). Generation of first strand cDNA was
performed as described previously.23 The reverse tran-
scriptase reaction products were used for quantitative
real-time PCR amplification, which was performed with
MyiQ single-color real-time detection system for quantifi-
cation with SYBR Green and melting curve analysis (Bio-
Rad, Richmond, CA). Primers for hBD-2, SKALP/elafin,
TNF-, CXCL-8, and the housekeeping gene human
acidic ribosomal protein P0 (hARP) were obtained from
Biolegio (Malden, The Netherlands). DNA was PCR-am-
plified using iQ SYBR Green Supermix (Bio-Rad, Her-
cules, CA) under the following conditions: 2 minutes at
50°C and 10 minutes at 95°C followed by 40 cycles of 15
minutes at 95°C and 1 minute at 60°C, with data collec-
tion in the last 30 seconds. All primer concentrations were
300 nmol/L in a total reaction volume of 25 l. The amount
of each mRNA was normalized to the amount of hARP in
the same sample. Relative mRNA expression levels of all
examined genes were measured using the comparative
2CT method.24
Histology and Immunohistochemistry
Human skin equivalents were fixed in buffered 4% formalin
for 4 hours, and processed for routine histology. Skin equiv-
alents were embedded in paraffin, and 6-m sections were
cut. Sections were stained with hematoxylin and eosin
(H&E) or processed for immunohistochemical staining us-
ing an indirect immunoperoxidase technique with avidin-
biotin complex enhancement. To study epidermal prolifera-
tion, an antibody directed against Ki-67 (MIB-1; Immunotech,
SA, Marseilles, France) was used whereas epidermal dif-
ferentiation was studied using an antibodies directed
against cytokeratin 10 (clone RKSE60; Sanbio, Uden,
The Netherlands) and cytokeratin 16 (Novacastra, New-
castle-On Tyne, UK). SKALP/elafin was stained using poly-
clonal antibodies as described previously25 and hBD-2 was
stained using goat anti-hBD-2 polyclonal serum derived
from Peprotech (London, UK).
Statistics
Statistical analysis was performed using the Statistica
software package (Statsoft Inc., Tulsa, OK). Analysis of
qPCR data were done on the Ct values, using a paired
t-test or analysis of variance (repeated design), followed
by posthoc testing (Duncan’s multiple range test).
Results
A Model for Normal Human Epidermis: Adult
Versus Foreskin Keratinocytes
Adult abdominal keratinocytes were seeded on DED, and
cultured for 4 days submerged followed by 10 days
culturing at the air-liquid interface. To obtain a well-dif-
ferentiated epithelium that would lack expression of pso-
riasis-associated genes, the effect of a number of rele-
vant growth factors in a chemically defined medium that
lacked serum or bovine pituitary extract, was examined.
This was done in various concentrations of these factors,
either alone or in combination, and the effect on morphol-
ogy and expression of SKALP/elafin, hBD-2, and CK16
by the keratinocytes was examined by quantitative real-
time PCR (qPCR) and histology. We found that a combi-
nation of 5 ng/ml of KGF and 2 ng/ml of EGF in the
medium during the air-liquid interface culture was optimal
to obtain a good morphology of the epithelium of the skin
equivalent, as demonstrated by H&E staining (Figure 1).
The cells were shown to attach to the DED in the sub-
merged phase (Figure 1A), followed by formation of a mul-
tilayered epithelium during the air-liquid interface culture
(Figure 1, B–D). At day 7 of the air-liquid interface culture,
differentiation of the epitheliumwas shown as demonstrated
by the development of a granular and a cornified cell layer
(Figure 1C). After 10 days culturing at the air-liquid inter-
face, a well-differentiated fully stratified epithelium was
formed (Figure 1D). As shown by immunohistochemistry,
normal expression of CK10 was noted (Figure 2B) whereas
no expression of SKALP/elafin, hBD-2, or CK16 was de-
tected (Figure 2, C–E). This pattern of protein expression,
which is also found in normal skin in vivo, was consistently
noted in primary cells derived from more than 10 different
donors. Because most commercially available skin equiva-
Figure 1. Development of normal human skin equivalents. Adult human keratinocytes were seeded on DED, and cultured for 4 days submerged, followed by
0 (A), 3 (B), 7 (C), or 10 (D) days of culturing at the air-liquid interface. Skin equivalents were stained for H&E.
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lents use foreskin keratinocytes, we generated skin con-
structs from neonatal foreskins, for comparison. Under the
conditions used here, the constructs containing fore-
skin keratinocytes displayed parakeratosis (Figure 2F) and
consistently expressed the psoriasis-associated marker
SKALP/elafin (Figure 2J). Expression of the other marker
genes was similar to that found in abdominal keratinocytes
(Figure 2, G–I). These results show that adult normal human
keratinocytes cultured at an air-liquid interface with defined
medium and two defined growth factors (EGF and KGF)
exhibit a normal stratification and a protein expression pro-
file found in normal human epidermis.
Pro-Inflammatory Cytokines Induce a Psoriasis-
Associated Gene Expression Signature in
Normal Human Skin Equivalents
To induce a psoriatic phenotype in the normal human skin
equivalents, the constructs were stimulated during the last 4
days of the air-liquid interface culture with various combi-
nations of IL-1, TNF-, and IL-6. mRNA was isolated, and
gene expression of SKALP/elafin and hBD-2 was deter-
mined by qPCR, see Figure 3, A and B, respectively. Treat-
ment of the skin constructs with any of the stimuli induced
an increase in expression of SKALP/elafin and/or hBD-2
compared to the control medium. The combination of IL-1,
TNF-, and IL-6 was found to induce significantly higher
expression levels of psoriasis-associated genes than any of
the other treatments. TNF- alone variably induced hBD-2
and SKALP/elafin expression, and high concentrations of
TNF- had a deleterious effect on epidermal morphology
(not shown). IL-6 alone moderately affected hBD-2 and
SKALP/elafin expression (not shown).
The effect of cytokine stimulation of the normal skin con-
structs was further investigated at the protein level by im-
munohistochemical analysis of SKALP/elafin and hBD-2
(Figure 4). In the control skin equivalents, no expression of
SKALP/elafin (Figure 4A) and hBD-2 (Figure 4E) could be
demonstrated. Stimulation with IL- alone (Figure 4, B and
F), or a combination of IL-1 and TNF- (Figure 4, C and G)
induced weak to moderate expression of SKALP/elafin and
hBD-2 protein in the upper layers of the epidermis. Stimu-
lation of the skin construct with the combination of IL-1,
TNF-, and IL-6 (Figure 4, D and H) induced high expres-
sion levels of both SKALP/elafin and hBD-2 protein in the
stratum granulosum and stratum spinosum, a pattern also
found in lesional psoriatic epidermis. In skin equivalents
with high epidermal hBD-2 expression, hBD-2 staining was
also found in the acellular dermal compartment (Figure 4H),
presumably by the interaction of secreted hBD-2, which is a
highly cationic protein, with negatively charged dermal
structures such as basal membranes. Cytokine stimulation
minimally affected morphology of the skin constructs.
To study the effects of pro-inflammatory cytokines on
epidermal differentiation expression of the normal differ-
entiation marker CK10 and the regeneration-associated
marker CK16 was determined by immunohistochemistry
(Figure 5). As shown before, control skin constructs
showed high CK10 expression in the suprabasal layers
(Figure 5A), whereas CK16 was almost absent in the skin
constructs (Figure 5E). Stimulation of the constructs with
IL-1, or a combination of IL-1 and TNF- did not affect
CK10 expression (Figure 5, B and C), whereas CK16
expression was slightly increased (Figure 5, F and G).
The combination of IL-1, TNF-, and IL-6 slightly de-
creased CK10 expression (Figure 5D), whereas CK16
expression was markedly increased (Figure 5H), showing
that cytokine stimulation affects differentiation of the skin
constructs in a way that is very similar to that found in
lesional psoriatic epidermis.
Another hallmark of lesional psoriatic skin are high
levels of inflammatory mediators produced both by infil-
trate cells and the keratinocytes. We therefore measured
Figure 2. Comparison of adult and neonatal keratinocytes in the develop-
ment of normal human skin equivalents. Abdominal (A--E) or foreskin (F--J)
human keratinocytes were seeded on DED, and cultured for 4 days sub-
merged, followed by 10 days of culture at the air-liquid interface. Morphol-
ogy of the skin constructs was studied by H&E staining (A and F), whereas
protein expression of CK10 (B and G), CK16 (C and H), hBD-2 (D and I), and
SKALP/elafin (E and J) was determined by immunohistochemistry. Note the
expression of SKALP/elafin and the presence of parakeratosis in the con-
structs derived from neonatal foreskin keratinocytes.
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the expression of IL-8 and TNF- in cytokine-stimulated
normal human skin equivalents, using qPCR. The mixture
of cytokines that induced strong expression of SKALP/
elafin, hBD-2, and CK16 was also shown to increase
gene expression of both TNF- (Figure 6A) and IL-8
(Figure 6B), as compared to the control skin construct.
Because recent studies have suggested a role for Th17
cell-derived cytokines in psoriasis we studied the effect of
IL-22 on the skin equivalents. Figure 7 demonstrates that
IL-22 induces a dose-dependent induction of hBD-2 protein
expression as determined by immunohistochemistry. No
effect was noted on epidermal morphology or cellular pro-
liferation (not shown).
Response of Epidermal Keratinocytes in the
Psoriatic Skin Equivalent to Anti-Psoriatic Drugs
We performed a limited validation of the psoriasis skin
equivalent model by testing the effect of selected anti-
psoriatic drugs. The prediction would be that drugs known
to target the epidermal compartment would show a thera-
peutic effect, whereas drugs that are mainly active against
T cells (absent in our model) would be without effect. Nor-
mal skin constructs were stimulated the last 4 days of the
air-liquid interface culture with a mixture of IL-1, TNF-,
and IL-6 in the presence or absence of all-trans retinoic acid
(ATRA) or cyclosporine A. Gene expression of SKALP/elafin
and hBD-2 in the epithelium was determined by qPCR, and
protein expression was determined by immunohistochem-
istry. ATRA was shown to inhibit cytokine-induced SKALP/
elafin (Figure 8A) and hBD-2 (Figure 8B) gene expression
as determined by qPCR. Also cytokine-induced SKALP/
elafin (Figure 9, A–C) and hBD-2 (Figure 9, D–F) protein
expression were inhibited by ATRA, suggesting a therapeu-
tic effect of ATRA, and illustrating the potential use of the
model for drug screening. ATRA also inhibited the expres-
sion of the normal differentiation marker CK10, which is a
known side effect of retinoid therapy in vivo (data not
shown). In contrast, no inhibition of cytokine-induced TNF-
and IL-8 expression by ATRA was shown (data not shown).
No significant effect of cyclosporine A on hBD-2 and
SKALP/elafin expression was noted in concentrations up to
106 mol/L (data not shown).
Discussion
In the present study we sought to develop skin model
systems, using a minimal set of relevant growth factors
and cytokines, that would reproducibly display morpho-
logical and molecular features of normal and psoriatic
epidermis. A chemically defined medium with EGF and
Figure 3. Effect of cytokine stimulation on
SKALP/elafin and hBD-2 gene expression in hu-
man skin equivalents. Skin equivalents were
stimulated the last 4 days of the air-liquid inter-
face culture with 10 ng/ml of IL-1, 10 ng/ml of
IL-1 and 5 ng/ml of TNF–, or 10 ng/ml of
IL-1, 5 ng/ml of TNF–, and 5 ng/ml of IL-6.
SKALP/elafin (A) and hBD-2 (B) gene expres-
sions were determined by qPCR. All stimuli in-
duced a significant induction of SKALP/elafin
(P  0.02) and hBD-2 (P  0.001) gene expres-
sion (analysis of variance, repeated design). The
cytokine mix of IL-1, TNF-, and IL-6 induced
a significantly higher expression of hBD-2 than
the other stimuli (P  0.05, Duncan’s multiple
range test).
Figure 4. Effect of cytokine stimulation on SKALP/elafin and hBD-2 protein expression in skin equivalents. Human skin equivalents were stimulated (B–D and
F–H) or not (A and E) for 4 days with 10 ng/ml of IL-1 (B and F); 10 ng/ml of IL-1 and 5 ng/ml of TNF- (C and G); or 10 ng/ml of IL-1, 5 ng/ml of TNF-,
and 5 ng/ml of IL-6 (D and H). SKALP/elafin (A–D) and hBD-2 (E–H) protein expression was determined by immunohistochemistry.
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KGF was found to stimulate development of normal epi-
dermis lacking psoriasis markers, whereas a combination
of IL-1, TNF-, and IL-6 induced expression of the pso-
riasis-associated proteins SKALP/elafin, hBD-2, and
CK16, and the pro-inflammatory cytokines TNF- and
IL-8. Pharmacological validation of the psoriasis model
illustrates the potential use of this model for drug screen-
ing, both for therapeutic actions and side effects.
In contrast to the model presented in this study, most
commercially available skin equivalents use foreskin ker-
atinocytes.26 We show that foreskin keratinocytes, at
least under the conditions used here, form an abnormal
epithelial phenotype, as shown by an abnormal morphol-
ogy and abnormal protein expression. Therefore, adult
human keratinocytes instead of foreskin keratinocytes are
the preferred cell type to develop normal human skin
equivalents. However, because the characteristics of
foreskin keratinocytes, including parakeratosis and ex-
pression of the psoriasis-associated protein SKALP/ela-
fin, are similar to that of psoriatic skin, one might argue
that foreskin keratinocytes as such might be useful for the
development of a skin equivalent model mimicking pso-
riatic skin.
Various submerged keratinocyte culture models have
been developed to study inflammatory skin diseases.14–
16,27,28 Recently, more advanced three-dimensional skin
equivalent models displaying characteristics of inflam-
matory diseases, including keratinocyte hyperprolifera-
tion and enhanced expression of inflammatory mediators,
have been developed.20–22 Fibroblasts, which are in-
cluded in these models,20–22 promote keratinocyte pro-
liferation and differentiation via the secretion of factors
such as KGF and GM-CSF.29,30 In our model, we showed
that addition of fibroblast-derived KGF to the skin equiv-
alents in combination with EGF results in the correct
morphological and molecular characteristics of normal
human skin, including the absence of the psoriasis-asso-
ciated proteins SKALP, hBD-2, and cytokeratin 16. It
should be noted that the cytokines used in our model
might have different effects, both qualitatively and quan-
titatively, in skin equivalent models containing fibroblasts.
In contrast to our model, the described models make use
of either primary keratinocytes from psoriatic donors,20
whose availability is limited, or cell lines,22 which may
behave different from primary keratinocytes. In addition,
in some models lymphocytes are included, which makes
the models complex and less defined.22 We show that a
well-defined psoriatic skin equivalent model can be ob-
tained, using relevant pro-inflammatory cytokines and
primary keratinocytes obtained from donors without a
history of psoriasis.
The development of a psoriatic phenotype in the skin
equivalents was studied by expression of the psoriasis-
associated proteins SKALP/elafin and hBD-2. The rele-
vance and the specificity of these peptides as surrogate
markers for psoriasis is indicated by the high expression
Figure 5. Effect of cytokine stimulation on CK10 and CK16 protein expression in skin equivalents. Human skin equivalents were stimulated (B–D and F–H) or
not (A and E) for 4 days with 10 ng/ml of IL-1 (B and F); 10 ng/ml of IL-1 and 5 ng/ml of TNF- (C and G); or 10 ng/ml of IL-1, 5 ng/ml of TNF-, and 5
ng/ml of IL6 (D and H). CK10 (A–D) and CK16 (E–H) protein expression was determined by immunohistochemistry.
Figure 6. Effect of pro-inflammatory cytokines
on gene expression of inflammatory mediators
by keratinocytes in skin equivalents. Skin equiv-
alents were stimulated the last 4 days of the
culture with the combination of 10 ng/ml of
IL-1, 5 ng/ml of TNF-, and 5 ng/ml of IL-6.
RNA was isolated and gene expression of TNF-
(A) and IL-8 (B) was determined by qPCR. Stim-
ulation with the cytokine mix significantly in-
duced TNF- (P  0.002) and IL-8 (P  0.02,
paired t-test).
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levels of both SKALP/elafin and hBD-2 in psoriatic le-
sions, but not in atopic dermatitis.5,31 Furthermore, -de-
fensins may also be causally involved in the disease,
because an increased copy number of -defensins was
associated with psoriasis.3 In vitro studies have demon-
strated that pro-inflammatory cytokines such as IL-1,
TNF-, and IL-6, which are present at high levels in
psoriatic lesions,6–9 induce expression of antimicrobial
peptides.32,33 Expression of hBD-2 in submerged cul-
tures of keratinocytes was shown to be induced by TNF-
and IL-1.33 Furthermore, IL-1 and IL-6 were shown to
increase expression of various antimicrobial peptides
and to enhance antibacterial properties of keratinocytes
in skin equivalents against the skin pathogens Escherichia
coli, Pseudomonas aeruginosa, and Staphylococcus au-
reus.32 Therefore, we used a mixture of the pro-inflamma-
tory cytokines IL-1, TNF-, and IL-6 to induce expres-
sion of the psoriasis-associated proteins SKALP/elafin
and hBD-2 in the skin equivalent model. The specific
combinations of pro-inflammatory cytokines were chosen
based on pilot experiments. The combination of cytokines
was shown to maximally increase expression of psoriasis-
associated proteins. Interestingly, although TNF- in-
creased IL-1-induced CK-16 expression, IL-1-induced
SKALP/elafin and hBD-2 expression were not affected by
TNF-. Addition of IL-6 to IL-1 and TNF- was shown to
increase both CK-16, and SKALP/elafin and hBD-2 expres-
sion. These results suggest that the individual cytokines
have specific functions in the pathology of psoriasis.
Recent studies have shown increased levels of IL-22
and oncostatin M in psoriatic lesions.9,10 Both skin equiv-
alent models and in vivo models have been used to study
the effects of IL-22 and oncostatin M on the epithelium.
IL-22 and oncostatin M were shown to increase expres-
sion of psoriasis-associated proteins, including hBD-2,
and to induce acanthosis, suggesting that IL-22 and
oncostatin M play an important role in psoriasis.34–37 We
show that in addition to the pro-inflammatory cytokines
IL-1, TNF-, and IL-6, also IL-22 increased hBD-2 ex-
pression in the skin equivalents. This shows that in addi-
tion to cytokines that have been associated with psoriasis
in the context of Th1 responses, also Th17 cell-derived
cytokines can induce psoriasis features in the skin equiv-
alent model.
High expression levels of both TNF- and IL-8 have
been demonstrated in psoriatic lesions, and these factors
may play an important role in psoriasis by mediating
chemotaxis of different inflammatory cell types and reg-
ulation of the inflammatory response in keratinocytes.6,7,9
Studies using anti-TNF- based therapies in psoriasis
patients show very promising results, supporting the im-
portant role for TNF- in the pathology of psoriasis.11,12
We show that in addition to increasing expression of the
psoriasis-associated proteins SKALP/elafin and hBD-2,
the mixture of cytokines significantly increased gene ex-
pression of the pro-inflammatory cytokines IL-8 and
TNF- in keratinocytes. These results are in line with
studies showing that TNF- and IL-8 production by ker-
atinocytes is stimulated by cytokines such as IL-1, IL-6,
and TNF- itself.9
In addition to mediating the inflammatory process, pro-
inflammatory cytokines have also been demonstrated to
affect proliferation of keratinocyte.9 Both IL-8 and IL-6
have been shown to increase proliferation of keratino-
cytes, suggesting that stimulation of the skin constructs
with IL-6, which has direct proliferative activity, and
TNF- and IL-1, which indirectly affect proliferation via
production of IL-8, would result in increased proliferation
Figure 7. Effect of IL-22 on hBD-2 protein expression in skin equivalents. Human skin equivalents were stimulated the last 4 days of the culture with 0 (A), 30
(B), 100 (C), or 300 (D) ng/ml of IL-22. hBD-2 protein expression was determined by immunohistochemistry.
Figure 8. Effect of all-trans retinoic acid (ATRA)
on cytokine-induced SKALP/elafin and hBD-2
gene expression in skin equivalents. Human
skin equivalents were stimulated the last 4 days
of culture with a mixture of 10 ng/ml of IL-1, 5
ng/ml of TNF-, and 5 ng/ml of IL-6 (CM) in the
presence or absence of ATRA (106 or 107
mol/L). RNA was isolated, and gene expression
of SKALP/elafin (A) and hBD-2 (B) was deter-
mined by qPCR. Treatment with ATRA caused a
significant decrease of cytokine-induced expres-
sion of SKALP/elafin (P 0.05) and hBD-2 (P
0.01, analysis of variance, repeated design).
hBD-2 expression was significantly affected by
both ATRA concentrations (P  0.02) whereas
SKALP/elafin expression was only affected by
the highest ATRA concentration (P 0.05, Dun-
can’s multiple range test).
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of the skin constructs. However, in the skin constructs
produced here, we did not observe increased prolifera-
tion after stimulation with the mixture of cytokines. This
may be explained by the anti-proliferative effect of TNF-,
or by absence of the relevant psoriasis-specific mitogen
in our model system. Alternatively, this may be a generic
limitation of working with primary adult keratinocytes,
which appear to have little proliferative capacity in vitro
anyway. We found that the proliferative potential of our
cultures is limited, and that the normal skin equivalents
cannot be maintained longer than 4 to 5 weeks after the
start of air exposure. This is in contrast with long-term
three-dimensional skin cultures described in literature,
which last for at least 12 weeks.38 Future studies are
directed to address this point in more detail, as it is
desirable to obtain a psoriatic skin construct that would
include hyperproliferation as a feature. The current isola-
tion methods for primary cells could select for transient
amplifying cells rather than stem cells. Obviously, this is
a possibility that should be further explored. Alternatively,
as already indicated, the use of foreskin keratinocytes
could be considered in the psoriasis model because
these cells have a larger proliferative capacity, and tend
to adopt a psoriatic phenotype anyway, without stimula-
tion. An interesting conclusion that can be drawn from
this observation is that, although CK16 is regarded as a
hyperproliferation-associated cytokeratin, in our model
system CK16 expression is not dependent on a hyper-
proliferative context.
Validation of the psoriatic skin equivalent model was
performed by the addition of all-trans retinoic acid
(ATRA) and cyclosporine A. Retinoids have been dem-
onstrated to interfere with terminal differentiation and pro-
liferation of keratinocytes via signaling through nuclear
retinoid receptors.39,40 ATRA is well recognized for its
reduction of early and late markers of normal differentia-
tion,41 and for its negative regulation of SKALP/elafin in
skin raft cultures.42 Furthermore, induction of hBD-2 ex-
pression by TNF- and IL-1 in submerged cultures of
keratinocytes was inhibited by ATRA.33 In line with these
observations, we show that ATRA inhibits expression of
the psoriasis-associated proteins SKALP/elafin and
hBD-2 in cytokine-stimulated skin equivalents, and re-
duces expression of the normal differentiation marker
CK10. These results demonstrate the potential use of the
psoriatic skin equivalent model for in vitro screening of
drugs that act on the epidermis, both for therapeutic
effects and side effects. In contrast to ATRA, the immu-
nomodulating drug cyclosporine A which acts on lym-
phocyte activation did not inhibit cytokine-induced
SKALP/elafin and hBD-2 expression.
We conclude that the presented model system is poten-
tially useful for studying biology of psoriasis, and could
provide a starting point to investigate the efficacy of poten-
tial anti-psoriatic drugs acting on keratinocytes.
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